BTCC / BTCC Square / Global Cryptocurrency /
Abbott Labs Q4 Earnings Miss on Revenue as Nutrition Sales Decline

Abbott Labs Q4 Earnings Miss on Revenue as Nutrition Sales Decline

Published:
2026-01-23 09:57:02
17
2
BTCCSquare news:

Abbott Laboratories shares tumbled 8% after reporting fourth-quarter revenue of $11.5 billion, falling short of Wall Street's $11.8 billion estimate. While adjusted EPS met expectations at $1.50, weak performance in the nutrition segment dragged down results.

The company's medical devices segment showed strength with 12% growth, and established pharmaceuticals ROSE 9%. However, nutrition sales plummeted 8.9% as price increases dampened consumer demand amid persistent commodity cost pressures.

Abbott maintained its 2026 guidance, projecting adjusted EPS between $5.55-$5.80 with organic sales growth of 6.5-7.5%. The $21 billion Exact Sciences acquisition remains on track for Q2 2026 closing.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.